FDA grants orphan drug status for Bio-Path’s Liposomal Grb-2 to treat AML
Currently, Liposomal Grb-2 is in a safety segment of a Phase II trial in combination with Ara-C for the treatment of AML. It is also being evaluated for
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.
LOWR HDV – 1 (LOnafarnib With and without Ritonavir-1) is a parallel dose comparison study which randomized subjects to receive different doses of lonafarnib with or without ritonavir